US Pharmaceuticals & Biotechnology "Generics & Biosimilars: Deep-dive on..."

Research evidence excerpt

US Pharmaceuticals & Biotechnology "Generics & Biosimilars: Deep-dive on..."

be an "opportunity" set vs. in the past it was perceived as a "risk". The US core generic Paritosh Gangaramani

pricing has been relatively stable and ~flat in recent years, while this was a cause of Associate Analyst

significant worry for the sector in the past (see prior deep-dive). From here, we see paritosh.gangaramani@ubs.com

numerous attractive launch opportunities due to significant Pharma patent cliff. +1-212-713 8073

Over next 5yrs, we see 84 key US drug markets opening up representing >$250bn

in pre-LOE revenue (Figure 1UpcomingLOECycle:OportunityforGenerics&Biosimilars(Actualmarketformationcouldbedelayedincertaininstances,seotherchartsbelow), Figure 284DrugsProfiled:AsesingGeneric/BiosimilarOportunity).

We define a holistic framework and analyze each of these market for overall

attractiveness (Figure 4BrandedDrugAtractivenesforGeneric/BiosimilarEntry(2026LOE), Figure 5BrandedDrugAtractivenesforGeneric/BiosimilarEntry(20272028LOE), Figure 6BrandedDrugAtractivenesforGeneric/BiosimilarEntry(20292030LOE)). The growth opportunity for Spec

Pharma companies for individual drugs is often a function of pre-LOE sales,

competitive intensity, manufacturing complexity, freedom to operate & entry

timing. We assign quantitative scores to rate each drug on individual metrics.

We highlight detailed status of US gx/biosim pipeline for Teva, Viatris, Amneal,

Alvotech, Dr. Reddy's, Aurobindo, Cipla, Lupin, Sun Pharma, Zydus (Pg 8-15).

Please email us for our detailed "generics tracker" identifying which companies are

pursuing what generic/ biosimilar and their status.

India Generics: increasing focus on biosimilar opportunities; Prefer Sun Pharma